2157 (2157) Fair Value & Analysis

Healthcare · Market cap HK$7.0B

2 2157 2157 · HK

PriceHK$4.14

Fair ValueHK$2.04

Upside-50.7%

Quality43/100

Watch 2157 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$1.53 – HK$2.55

Fair value as of: Jul 2, 2026

From 15 valuation models · updated today

Price vs Fair Value (12 months)

12‑month range HK$3.58 – HK$10.18 · fair‑value band HK$1.53 – HK$2.55 · the HK$4.14 price screens above the HK$2.04 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2157 (2157) currently trades at HK$4.14, while our model-based Fair Value estimate is HK$2.04 — implying the stock looks roughly 50.7% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2157 generated revenue of HK$935M at a net margin of 28.0%. Revenue grew 100.0% year over year. It earns a return on equity of 25.3%. Net debt stands at HK$205M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$935M

Revenue growth (YoY) +100%

Net margin 28.0%

Return on equity 25.3%

Free cash flow −HK$82.8M FY2025

P/E ratio 22.9

More key figures

Operating margin -7.4%

EPS (TTM) HK$0.0200

Net debt HK$205M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2157 reported revenue of HK$911M in FY2025 versus HK$0 in FY2021. Reported net income was HK$255M in FY2025.

Revenue

FY21 HK$0

FY22 HK$15.6M

FY23 HK$225M

FY24 HK$368M

FY25 HK$911M

Net income

FY21 −HK$1.0B

FY22 −HK$689M

FY23 −HK$22.1M

FY24 −HK$411M

FY25 HK$255M

Is 2157 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	449.62 MXN	-94%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€274.90	€211.40	-23%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$291.22	$111.44	-62%
Samsung Biologics Co 207940	1,000,000 KRW	1,091,384 KRW	+9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2157 (2157) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.04 versus a price of HK$4.14 — about −51% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2157?

Our model-based fair value for 2157 is HK$2.04 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$4.14.

What is the quality score of 2157?

2157 has a Quality Score of 43/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2157 (2157)?

2157 reported trailing-twelve-month revenue of about HK$935M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2157?

The net profit margin of 2157 is about 28.0%, meaning it keeps roughly 28.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.